Oxford

ECMC Oxford

Oxford ECMC aims to apply basic scientific discoveries in cancer biology to the development of novel cancer therapies and prognostic/diagnostic biomarkers to help individualise patient care. The Centre has expertise in immunology, DNA repair, angiogenesis and molecular pathology and has facilities for conducting imaging, proteomics, microarray and radioisotope studies.

Research Areas

Focus

Angiogenesis, Immunology, pharmacodynamics (PD), tumour vasculature and metastasis, DNA repair, immunotherapy, gene therapy and radiation oncology

Disease Area

Relevant to all types of cancer, bladder, breast, colon, rectal, kidney, lung, melanoma, non-Hodgkin's lymphoma, oesophageal, prostate, stomach

 

Goals

Goals

For further information on the goals and objectives of Oxford ECMC go to:

More about Goals

 

Skills

Skills

Oxford ECMC principal investigators and staff have a diverse range of skills and expertise.

More about Skills

 

Facilities

Facilities

Oxford ECMC has access to a range of research facilities that are utilised in studies.

More about Facilities

 

Achievements

Achievements

To learn more about the scientific and operational achievements of Oxford ECMC go to:

More Achievements

 

Centre Lead

Mark R. Middleton, PhD, FRCP
Professor of Experimental Cancer Medicine
& Consultant Medical Oncologist
Clinical Director, Oncology
University of Oxford 
Department of Oncology
Churchill Hospital
Oxford, OX3 7LJ
UK

 

General and Patient Enquiries

Mrs Lindsey Bettison
PA to Professor Mark Middleton
University Department of Oncology
Cancer & Haematology Centre
Level 2
Churchill Hospital
Oxford, OX3 7LJ

Tel: +44(0)1865 235315
Tel: +44(0)1865 235986

 

Clinical Trials Enquiries

You can also find out about trials recruiting in Oxford on the CancerHelp UK clinical trials database.